Ask which peptides work for weight loss and you get a list of eight or ten names. Semaglutide sits near the top, and then the list continues into AOD-9604, CJC-1295, ipamorelin, fragment 176-191, as though these were neighbouring entries on the same scale.
They are not on the same scale. They are not on the same scale in the way that a licensed airliner and a kit plane are both aircraft. Three compounds on that list have randomised trials in thousands of people. Most of the rest have nothing you can retrieve.
The three with real trials
Start with what is settled, because on this topic there is more of it than usual.
Semaglutide. A randomised trial tested once-weekly semaglutide 2.4 mg as an adjunct to lifestyle intervention in adults with overweight or obesity, to establish whether meaningful weight loss could be achieved.[1] That question is no longer open.
Tirzepatide. A randomised trial of once-weekly tirzepatide in adults with obesity did the same for a compound that hits two receptors instead of one.[2]
Retatrutide. The newest, and still earlier in its life. A phase 2 randomised trial examined dose-response for efficacy and safety in obesity, for a molecule that agonises three receptors at once.[3]
What “phase 2” means here: retatrutide has been tested for dose-finding, not yet through the large confirmatory trials that semaglutide and tirzepatide have. Promising and proven are different words.
Why these three and not others
The mechanism is specific, and knowing it lets you judge any new name that appears on a list.
Semaglutide reduces body weight through effects on appetite, energy intake and control of eating.[4] It does not accelerate metabolism or partition fat. It makes you eat less, by acting on the systems that decide when you have had enough. A separate trial in 72 adults with obesity examined how semaglutide 2.4 mg affects gastric emptying alongside appetite and energy intake.[5]
Tirzepatide extends the idea by acting at two receptors, GIP and GLP-1, rather than one. It is an engineered acylated peptide built to activate both.[6] Retatrutide adds a third, glucagon.
One, two, three receptors. That is the entire arc of this drug class so far, and it explains why the effective compounds all look like each other and unlike everything else on the list.
What the compounds sold as weight-loss peptides have
Now the other half of the list, which is where most readers of this query will end up shopping.
CJC-1295 is real and it does something measurable. A study of its pharmacokinetics and safety found prolonged stimulation of growth hormone and IGF-1 secretion in healthy adults.[7] Note precisely what was measured: hormone concentrations. Not body weight, not fat mass, not waist circumference. The compound raised a hormone that people associate with leanness, and the study reported the hormone.
This is the single most common error in the peptide market, and it is worth naming. A molecule that raises growth hormone has been shown to raise growth hormone. Whether that produces fat loss in a person is a different question, requiring a different trial, with body weight as the endpoint. Anabolic-steroid research went through the same confusion decades ago, when nitrogen-balance studies were read as proof of strength gains that later trials had to establish separately.
Tesamorelin is the interesting exception, and it shows what a real result looks like. It is a growth hormone-releasing hormone analogue that specifically targets visceral fat, and a trial measured its effect on visceral and liver fat in HIV-infected patients with abdominal adiposity.[8] That is a genuine fat-reduction finding. It is also in a specific population with a specific condition, which is not the same as a weight-loss drug for the general public.
AOD-9604 is where this article has to stop and admit a gap. It is marketed widely as a fat-loss peptide, and I could not find a trial of it. Two separate search passes across Europe PMC, PubMed and Crossref returned a rimonabant review, a general sports-medicine paper, and, memorably, a study of air pollution and mortality. If a randomised trial of AOD-9604 in humans exists, this research did not surface it.
A compound with no retrievable trial is not a compound with a small effect. It is a compound nobody has published on. Those are different situations, and only one of them is a reason to wait.
What the effective ones cost you
The drugs that work have real side effects, which is generally how you can tell they are doing something.
Gastrointestinal effects are the common ones. A review of GLP-1 receptor agonists in non-diabetic patients with obesity notes they are effective for weight loss and cause gastrointestinal side effects.[9] Nausea is the headline.
The weight comes back. The STEP 1 trial extension followed 1961 adults after treatment withdrawal, examining body weight and cardiometabolic risk factors once the drug stopped.[10] This is the most under-discussed fact about the whole class.
Some of what you lose is muscle. A meta-analysis examined the effect of GLP-1 receptor agonists and co-agonists on body composition, undertaken specifically because the impact on lean mass was uncertain.[11]
That second point deserves more weight than it gets. These are not courses. The trials that established the effect kept people on the drug, and the withdrawal data is why.
Where you would get them
Semaglutide is approved by the regulator under specific brand names, and compounded versions sold outside those approvals have proliferated on the back of that popularity.[12]
That sentence contains the practical problem. The evidence in this article attaches to the approved product tested in the trial. A compounded or grey-market vial with the same name on it is not the thing that was studied, and its contents, concentration and purity were not part of any trial. You can be exactly right about the pharmacology and still be wrong about what is in the bottle.
How to read the next list you see
You will encounter more of these lists. Here is the test that separates the entries:
Was body weight the measured outcome? Not hormone levels, not fat oxidation in a cell line. Weight, in people, against a placebo.
How many people, and were they randomised? Thousands and yes, for semaglutide and tirzepatide. Fewer and earlier, for retatrutide. Neither, for most of the rest.
Does the list explain why one compound has trials and another does not? If every name gets a similar paragraph, the list is treating an approved drug and an unstudied research chemical as comparable options. They are not comparable, and a list that implies otherwise is not informing you.
The honest answer to “what are the best peptides for weight loss” is short and slightly boring: the ones your doctor can prescribe, which have been tested in large randomised trials, and which you would need to keep taking. Everything else on the list is either studied for something other than weight, or not studied at all.
This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.
References
Once-Weekly Semaglutide in Adults with Overweight or Obesity.. The New England journal of medicine, 2021.
Tirzepatide Once Weekly for the Treatment of Obesity.. The New England journal of medicine, 2022.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.. The New England journal of medicine, 2023.
Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.. Diabetes, obesity & metabolism, 2017.
The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity.. Diabetes, obesity & metabolism, 2021.
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.. Cardiovascular diabetology, 2022.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.. The Journal of clinical endocrinology and metabolism, 2006.
Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis.. International journal of obesity (2005), 2025.
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.. Diabetes, obesity & metabolism, 2022.
Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis.. Metabolism: clinical and experimental, 2025.
Navigating compounded semaglutide: what health care providers need to know.. The American journal of managed care, 2025.
